APO Research
Talk to an analyst

APO RESEARCH · REPORT

Targeted Drugs for Neurodegenerative Diseases

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Targeted Drugs for Neurodegenerative Diseases Market Analysis and Forecast 2026-2032

27 December 2025202 pages

Choose your research edition.

Industry ResearchTargeted Drugs for Neurodegenerative Diseases Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Targeted Drugs for Neurodegenerative Diseases Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Targeted Drugs for Neurodegenerative Diseases Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Targeted Drugs for Neurodegenerative Diseases Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Targeted Drugs for Neurodegenerative Diseases Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Targeted Drugs for Neurodegenerative Diseases market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Targeted Drugs for Neurodegenerative Diseases is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Targeted Drugs for Neurodegenerative Diseases is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Targeted Drugs for Neurodegenerative Diseases is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Targeted Drugs for Neurodegenerative Diseases is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Targeted Drugs for Neurodegenerative Diseases include Eisai Inc., Teva, NOVARTIS, Green Valley, Roche, Lundbeck, Eli Lilly, Biogen and UCB, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Targeted Drugs for Neurodegenerative Diseases, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Targeted Drugs for Neurodegenerative Diseases, also provides the revenue of main regions and countries. Of the upcoming market potential for Targeted Drugs for Neurodegenerative Diseases, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Targeted Drugs for Neurodegenerative Diseases revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Targeted Drugs for Neurodegenerative Diseases market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Targeted Drugs for Neurodegenerative Diseases revenue, projected growth trends, production technology, application and end-user industry.

Targeted Drugs for Neurodegenerative Diseases Segment by Company

Eisai Inc.

Teva

NOVARTIS

Green Valley

Roche

Lundbeck

Eli Lilly

Biogen

UCB

Supernus Pharmaceuticals

Sumitomo Pharma

Sanofi

Neurocrine

Kyowa Kirin

Janssen

Bristol-Myers Squibb

Acadia Pharmaceuticals Inc.

Targeted Drugs for Neurodegenerative Diseases Segment by Type

Oral

Injection

Targeted Drugs for Neurodegenerative Diseases Segment by Application

Parkinson's Disease (PD)

Huntington's Disease (HD)

Multiple Sclerosis (MS)

Tardive Dyskinesia (TD)

Alzheimer's Disease (AD)

Targeted Drugs for Neurodegenerative Diseases Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Targeted Drugs for Neurodegenerative Diseases market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Targeted Drugs for Neurodegenerative Diseases and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Targeted Drugs for Neurodegenerative Diseases.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Targeted Drugs for Neurodegenerative Diseases in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Targeted Drugs for Neurodegenerative Diseases company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Targeted Drugs for Neurodegenerative Diseases revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Oral Major Player Table 3. Injection Major Player Table 4. Global Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Parkinson's Disease (PD) Major Player Table 6. Huntington's Disease (HD) Major Player Table 7. Multiple Sclerosis (MS) Major Player Table 8. Tardive Dyskinesia (TD) Major Player Table 9. Alzheimer's Disease (AD) Major Player Table 10. Targeted Drugs for Neurodegenerative Diseases Industry Trends Table 11. Targeted Drugs for Neurodegenerative Diseases Industry Drivers Table 12. Targeted Drugs for Neurodegenerative Diseases Industry Opportunities and Challenges Table 13. Targeted Drugs for Neurodegenerative Diseases Industry Restraints Table 14. Global Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Targeted Drugs for Neurodegenerative Diseases Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Targeted Drugs for Neurodegenerative Diseases Market Share by Region (2021-2026) Table 17. Global Targeted Drugs for Neurodegenerative Diseases Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Targeted Drugs for Neurodegenerative Diseases Market Share by Region (2027-2032) Table 19. Global Targeted Drugs for Neurodegenerative Diseases Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Players (2021-2026) Table 21. Global Targeted Drugs for Neurodegenerative Diseases Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Targeted Drugs for Neurodegenerative Diseases Key Players Headquarters & Area Served Table 23. Global Targeted Drugs for Neurodegenerative Diseases Players, Product Type & Application Table 24. Global Targeted Drugs for Neurodegenerative Diseases Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Targeted Drugs for Neurodegenerative Diseases by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Targeted Drugs for Neurodegenerative Diseases Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Targeted Drugs for Neurodegenerative Diseases Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Targeted Drugs for Neurodegenerative Diseases Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Type (2021-2026) Table 31. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Type (2027-2032) Table 32. Global Targeted Drugs for Neurodegenerative Diseases Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Targeted Drugs for Neurodegenerative Diseases Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Targeted Drugs for Neurodegenerative Diseases Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Application (2021-2026) Table 36. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Application (2027-2032) Table 37. Eisai Inc. Company Information Table 38. Eisai Inc. Business Overview Table 39. Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 41. Eisai Inc. Recent Development Table 42. Teva Company Information Table 43. Teva Business Overview Table 44. Teva Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Teva Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 46. Teva Recent Development Table 47. NOVARTIS Company Information Table 48. NOVARTIS Business Overview Table 49. NOVARTIS Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. NOVARTIS Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 51. NOVARTIS Recent Development Table 52. Green Valley Company Information Table 53. Green Valley Business Overview Table 54. Green Valley Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Green Valley Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 56. Green Valley Recent Development Table 57. Roche Company Information Table 58. Roche Business Overview Table 59. Roche Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Roche Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 61. Roche Recent Development Table 62. Lundbeck Company Information Table 63. Lundbeck Business Overview Table 64. Lundbeck Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Lundbeck Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 66. Lundbeck Recent Development Table 67. Eli Lilly Company Information Table 68. Eli Lilly Business Overview Table 69. Eli Lilly Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Eli Lilly Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 71. Eli Lilly Recent Development Table 72. Biogen Company Information Table 73. Biogen Business Overview Table 74. Biogen Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Biogen Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 76. Biogen Recent Development Table 77. UCB Company Information Table 78. UCB Business Overview Table 79. UCB Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. UCB Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 81. UCB Recent Development Table 82. Supernus Pharmaceuticals Company Information Table 83. Supernus Pharmaceuticals Business Overview Table 84. Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 86. Supernus Pharmaceuticals Recent Development Table 87. Sumitomo Pharma Company Information Table 88. Sumitomo Pharma Business Overview Table 89. Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 91. Sumitomo Pharma Recent Development Table 92. Sanofi Company Information Table 93. Sanofi Business Overview Table 94. Sanofi Targeted Drugs for Neurodegenerative Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Sanofi Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 96. Sanofi Recent Development Table 97. Neurocrine Company Information Table 98. Neurocrine Business Overview Table 99. Neurocrine Targeted Drugs for Neurodegenerative Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Neurocrine Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 101. Neurocrine Recent Development Table 102. Kyowa Kirin Company Information Table 103. Kyowa Kirin Business Overview Table 104. Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 106. Kyowa Kirin Recent Development Table 107. Janssen Company Information Table 108. Janssen Business Overview Table 109. Janssen Targeted Drugs for Neurodegenerative Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Janssen Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 111. Janssen Recent Development Table 112. Bristol-Myers Squibb Company Information Table 113. Bristol-Myers Squibb Business Overview Table 114. Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 116. Bristol-Myers Squibb Recent Development Table 117. Acadia Pharmaceuticals Inc. Company Information Table 118. Acadia Pharmaceuticals Inc. Business Overview Table 119. Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 121. Acadia Pharmaceuticals Inc. Recent Development Table 122. North America Targeted Drugs for Neurodegenerative Diseases Revenue by Type (2021-2026) & (US$ Million) Table 123. North America Targeted Drugs for Neurodegenerative Diseases Revenue by Type (2027-2032) & (US$ Million) Table 124. North America Targeted Drugs for Neurodegenerative Diseases Revenue by Application (2021-2026) & (US$ Million) Table 125. North America Targeted Drugs for Neurodegenerative Diseases Revenue by Application (2027-2032) & (US$ Million) Table 126. North America Targeted Drugs for Neurodegenerative Diseases Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 127. North America Targeted Drugs for Neurodegenerative Diseases Revenue by Country (2021-2026) & (US$ Million) Table 128. North America Targeted Drugs for Neurodegenerative Diseases Revenue by Country (US$ Million) & (2027-2032) Table 129. Europe Targeted Drugs for Neurodegenerative Diseases Revenue by Type (2021-2026) & (US$ Million) Table 130. Europe Targeted Drugs for Neurodegenerative Diseases Revenue by Type (2027-2032) & (US$ Million) Table 131. Europe Targeted Drugs for Neurodegenerative Diseases Revenue by Application (2021-2026) & (US$ Million) Table 132. Europe Targeted Drugs for Neurodegenerative Diseases Revenue by Application (2027-2032) & (US$ Million) Table 133. Europe Targeted Drugs for Neurodegenerative Diseases Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 134. Europe Targeted Drugs for Neurodegenerative Diseases Revenue by Country (2021-2026) & (US$ Million) Table 135. Europe Targeted Drugs for Neurodegenerative Diseases Revenue by Country (US$ Million) & (2027-2032) Table 136. China Targeted Drugs for Neurodegenerative Diseases Revenue by Type (2021-2026) & (US$ Million) Table 137. China Targeted Drugs for Neurodegenerative Diseases Revenue by Type (2027-2032) & (US$ Million) Table 138. China Targeted Drugs for Neurodegenerative Diseases Revenue by Application (2021-2026) & (US$ Million) Table 139. China Targeted Drugs for Neurodegenerative Diseases Revenue by Application (2027-2032) & (US$ Million) Table 140. Asia Targeted Drugs for Neurodegenerative Diseases Revenue by Type (2021-2026) & (US$ Million) Table 141. Asia Targeted Drugs for Neurodegenerative Diseases Revenue by Type (2027-2032) & (US$ Million) Table 142. Asia Targeted Drugs for Neurodegenerative Diseases Revenue by Application (2021-2026) & (US$ Million) Table 143. Asia Targeted Drugs for Neurodegenerative Diseases Revenue by Application (2027-2032) & (US$ Million) Table 144. Asia Targeted Drugs for Neurodegenerative Diseases Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 145. Asia Targeted Drugs for Neurodegenerative Diseases Revenue by Region (US$ Million) & (2021-2026) Table 146. Asia Targeted Drugs for Neurodegenerative Diseases Revenue by Region (US$ Million) & (2027-2032) Table 147. SAMEA Targeted Drugs for Neurodegenerative Diseases Revenue by Type (2021-2026) & (US$ Million) Table 148. SAMEA Targeted Drugs for Neurodegenerative Diseases Revenue by Type (2027-2032) & (US$ Million) Table 149. SAMEA Targeted Drugs for Neurodegenerative Diseases Revenue by Application (2021-2026) & (US$ Million) Table 150. SAMEA Targeted Drugs for Neurodegenerative Diseases Revenue by Application (2027-2032) & (US$ Million) Table 151. SAMEA Targeted Drugs for Neurodegenerative Diseases Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 152. SAMEA Targeted Drugs for Neurodegenerative Diseases Revenue by Country (2021-2026) & (US$ Million) Table 153. SAMEA Targeted Drugs for Neurodegenerative Diseases Revenue by Country (US$ Million) & (2027-2032) Table 154. Research Programs/Design for This Report Table 155. Authors List of This Report Table 156. Secondary Sources Table 157. Primary Sources List of Figures Figure 1. Targeted Drugs for Neurodegenerative Diseases Image Figure 2. Global Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Targeted Drugs for Neurodegenerative Diseases Market Size Share 2021 VS 2025 VS 2032 Figure 4. Oral Image Figure 5. Injection Image Figure 6. Global Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Targeted Drugs for Neurodegenerative Diseases Market Size Share 2021 VS 2025 VS 2032 Figure 8. Parkinson's Disease (PD) Image Figure 9. Huntington's Disease (HD) Image Figure 10. Multiple Sclerosis (MS) Image Figure 11. Tardive Dyskinesia (TD) Image Figure 12. Alzheimer's Disease (AD) Image Figure 13. Global Targeted Drugs for Neurodegenerative Diseases Market Size (US$ Million) & (2021-2032) Figure 14. Global Targeted Drugs for Neurodegenerative Diseases Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Targeted Drugs for Neurodegenerative Diseases Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Targeted Drugs for Neurodegenerative Diseases Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Targeted Drugs for Neurodegenerative Diseases Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Type (2021-2032) Figure 21. Global Targeted Drugs for Neurodegenerative Diseases Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Application (2021-2032) Figure 24. North America Targeted Drugs for Neurodegenerative Diseases Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Targeted Drugs for Neurodegenerative Diseases Revenue Share by Type (2021-2032) Figure 26. North America Targeted Drugs for Neurodegenerative Diseases Revenue Share by Application (2021-2032) Figure 27. North America Targeted Drugs for Neurodegenerative Diseases Revenue Share by Country (2021-2032) Figure 28. United States Targeted Drugs for Neurodegenerative Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Targeted Drugs for Neurodegenerative Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Targeted Drugs for Neurodegenerative Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Targeted Drugs for Neurodegenerative Diseases Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Targeted Drugs for Neurodegenerative Diseases Revenue Share by Type (2021-2032) Figure 33. Europe Targeted Drugs for Neurodegenerative Diseases Revenue Share by Application (2021-2032) Figure 34. Europe Targeted Drugs for Neurodegenerative Diseases Revenue Share by Country (2021-2032) Figure 35. Germany Targeted Drugs for Neurodegenerative Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Targeted Drugs for Neurodegenerative Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Targeted Drugs for Neurodegenerative Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Targeted Drugs for Neurodegenerative Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Targeted Drugs for Neurodegenerative Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Targeted Drugs for Neurodegenerative Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Targeted Drugs for Neurodegenerative Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Targeted Drugs for Neurodegenerative Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Targeted Drugs for Neurodegenerative Diseases Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Targeted Drugs for Neurodegenerative Diseases Revenue Share by Type (2021-2032) Figure 45. China Targeted Drugs for Neurodegenerative Diseases Revenue Share by Application (2021-2032) Figure 46. Asia Targeted Drugs for Neurodegenerative Diseases Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Targeted Drugs for Neurodegenerative Diseases Revenue Share by Type (2021-2032) Figure 48. Asia Targeted Drugs for Neurodegenerative Diseases Revenue Share by Application (2021-2032) Figure 49. Asia Targeted Drugs for Neurodegenerative Diseases Revenue Share by Region (2021-2032) Figure 50. Japan Targeted Drugs for Neurodegenerative Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Targeted Drugs for Neurodegenerative Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Targeted Drugs for Neurodegenerative Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Targeted Drugs for Neurodegenerative Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Targeted Drugs for Neurodegenerative Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Targeted Drugs for Neurodegenerative Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Targeted Drugs for Neurodegenerative Diseases Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Targeted Drugs for Neurodegenerative Diseases Revenue Share by Type (2021-2032) Figure 58. SAMEA Targeted Drugs for Neurodegenerative Diseases Revenue Share by Application (2021-2032) Figure 59. SAMEA Targeted Drugs for Neurodegenerative Diseases Revenue Share by Country (2021-2032) Figure 60. Brazil Targeted Drugs for Neurodegenerative Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Targeted Drugs for Neurodegenerative Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Targeted Drugs for Neurodegenerative Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Targeted Drugs for Neurodegenerative Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Targeted Drugs for Neurodegenerative Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Targeted Drugs for Neurodegenerative Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Targeted Drugs for Neurodegenerative Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Targeted Drugs for Neurodegenerative Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Targeted Drugs for Neurodegenerative Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Targeted Drugs for Neurodegenerative Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Targeted Drugs for Neurodegenerative Diseases Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Injection
Applications
  • Parkinson's Disease (PD)
  • Huntington's Disease (HD)
  • Multiple Sclerosis (MS)
  • Tardive Dyskinesia (TD)
  • Alzheimer's Disease (AD)
Companies covered
  • Eisai Inc.
  • Teva
  • NOVARTIS
  • Green Valley
  • Roche
  • Lundbeck
  • Eli Lilly
  • Biogen
  • UCB
  • Supernus Pharmaceuticals
  • Sumitomo Pharma
  • Sanofi
  • Neurocrine
  • Kyowa Kirin
  • Janssen
  • Bristol-Myers Squibb
  • Acadia Pharmaceuticals Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Targeted Drugs for Neurodegenerative Diseases Market by Type
  3. 1.2.1 Global Targeted Drugs for Neurodegenerative Diseases Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Oral
  5. 1.2.3 Injection
  6. 1.3 Targeted Drugs for Neurodegenerative Diseases Market by Application
  7. 1.3.1 Global Targeted Drugs for Neurodegenerative Diseases Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Parkinson's Disease (PD)
  9. 1.3.3 Huntington's Disease (HD)
  10. 1.3.4 Multiple Sclerosis (MS)
  11. 1.3.5 Tardive Dyskinesia (TD)
  12. 1.3.6 Alzheimer's Disease (AD)
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Targeted Drugs for Neurodegenerative Diseases Market Dynamics
  1. 2.1 Targeted Drugs for Neurodegenerative Diseases Industry Trends
  2. 2.2 Targeted Drugs for Neurodegenerative Diseases Industry Drivers
  3. 2.3 Targeted Drugs for Neurodegenerative Diseases Industry Opportunities and Challenges
  4. 2.4 Targeted Drugs for Neurodegenerative Diseases Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Targeted Drugs for Neurodegenerative Diseases Market Perspective (2021-2032)
  2. 3.2 Global Targeted Drugs for Neurodegenerative Diseases Growth Trends by Region
  3. 3.2.1 Global Targeted Drugs for Neurodegenerative Diseases Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Targeted Drugs for Neurodegenerative Diseases Market Size by Region (2021-2026)
  5. 3.2.3 Global Targeted Drugs for Neurodegenerative Diseases Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Targeted Drugs for Neurodegenerative Diseases Revenue by Players
  2. 4.1.1 Global Targeted Drugs for Neurodegenerative Diseases Revenue by Players (2021-2026)
  3. 4.1.2 Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Targeted Drugs for Neurodegenerative Diseases Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Targeted Drugs for Neurodegenerative Diseases Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Targeted Drugs for Neurodegenerative Diseases Key Players Headquarters & Area Served
  7. 4.4 Global Targeted Drugs for Neurodegenerative Diseases Players, Product Type & Application
  8. 4.5 Global Targeted Drugs for Neurodegenerative Diseases Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Targeted Drugs for Neurodegenerative Diseases Market CR5 and HHI
  11. 4.6.3 2025 Targeted Drugs for Neurodegenerative Diseases Tier 1, Tier 2, and Tier 3
5 Targeted Drugs for Neurodegenerative Diseases Market Size by Type
  1. 5.1 Global Targeted Drugs for Neurodegenerative Diseases Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Targeted Drugs for Neurodegenerative Diseases Revenue by Type (2021-2032)
  3. 5.3 Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Type (2021-2032)
6 Targeted Drugs for Neurodegenerative Diseases Market Size by Application
  1. 6.1 Global Targeted Drugs for Neurodegenerative Diseases Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Targeted Drugs for Neurodegenerative Diseases Revenue by Application (2021-2032)
  3. 6.3 Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Eisai Inc.
  2. 7.1.1 Eisai Inc. Company Information
  3. 7.1.2 Eisai Inc. Business Overview
  4. 7.1.3 Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  6. 7.1.5 Eisai Inc. Recent Developments
  7. 7.2 Teva
  8. 7.2.1 Teva Company Information
  9. 7.2.2 Teva Business Overview
  10. 7.2.3 Teva Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Teva Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  12. 7.2.5 Teva Recent Developments
  13. 7.3 NOVARTIS
  14. 7.3.1 NOVARTIS Company Information
  15. 7.3.2 NOVARTIS Business Overview
  16. 7.3.3 NOVARTIS Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2021-2026)
  17. 7.3.4 NOVARTIS Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  18. 7.3.5 NOVARTIS Recent Developments
  19. 7.4 Green Valley
  20. 7.4.1 Green Valley Company Information
  21. 7.4.2 Green Valley Business Overview
  22. 7.4.3 Green Valley Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Green Valley Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  24. 7.4.5 Green Valley Recent Developments
  25. 7.5 Roche
  26. 7.5.1 Roche Company Information
  27. 7.5.2 Roche Business Overview
  28. 7.5.3 Roche Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Roche Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  30. 7.5.5 Roche Recent Developments
  31. 7.6 Lundbeck
  32. 7.6.1 Lundbeck Company Information
  33. 7.6.2 Lundbeck Business Overview
  34. 7.6.3 Lundbeck Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Lundbeck Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  36. 7.6.5 Lundbeck Recent Developments
  37. 7.7 Eli Lilly
  38. 7.7.1 Eli Lilly Company Information
  39. 7.7.2 Eli Lilly Business Overview
  40. 7.7.3 Eli Lilly Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Eli Lilly Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  42. 7.7.5 Eli Lilly Recent Developments
  43. 7.8 Biogen
  44. 7.8.1 Biogen Company Information
  45. 7.8.2 Biogen Business Overview
  46. 7.8.3 Biogen Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Biogen Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  48. 7.8.5 Biogen Recent Developments
  49. 7.9 UCB
  50. 7.9.1 UCB Company Information
  51. 7.9.2 UCB Business Overview
  52. 7.9.3 UCB Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2021-2026)
  53. 7.9.4 UCB Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  54. 7.9.5 UCB Recent Developments
  55. 7.10 Supernus Pharmaceuticals
  56. 7.10.1 Supernus Pharmaceuticals Company Information
  57. 7.10.2 Supernus Pharmaceuticals Business Overview
  58. 7.10.3 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  60. 7.10.5 Supernus Pharmaceuticals Recent Developments
  61. 7.11 Sumitomo Pharma
  62. 7.11.1 Sumitomo Pharma Company Information
  63. 7.11.2 Sumitomo Pharma Business Overview
  64. 7.11.3 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  66. 7.11.5 Sumitomo Pharma Recent Developments
  67. 7.12 Sanofi
  68. 7.12.1 Sanofi Company Information
  69. 7.12.2 Sanofi Business Overview
  70. 7.12.3 Sanofi Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Sanofi Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  72. 7.12.5 Sanofi Recent Developments
  73. 7.13 Neurocrine
  74. 7.13.1 Neurocrine Company Information
  75. 7.13.2 Neurocrine Business Overview
  76. 7.13.3 Neurocrine Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Neurocrine Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  78. 7.13.5 Neurocrine Recent Developments
  79. 7.14 Kyowa Kirin
  80. 7.14.1 Kyowa Kirin Company Information
  81. 7.14.2 Kyowa Kirin Business Overview
  82. 7.14.3 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  84. 7.14.5 Kyowa Kirin Recent Developments
  85. 7.15 Janssen
  86. 7.15.1 Janssen Company Information
  87. 7.15.2 Janssen Business Overview
  88. 7.15.3 Janssen Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Janssen Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  90. 7.15.5 Janssen Recent Developments
  91. 7.16 Bristol-Myers Squibb
  92. 7.16.1 Bristol-Myers Squibb Company Information
  93. 7.16.2 Bristol-Myers Squibb Business Overview
  94. 7.16.3 Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  96. 7.16.5 Bristol-Myers Squibb Recent Developments
  97. 7.17 Acadia Pharmaceuticals Inc.
  98. 7.17.1 Acadia Pharmaceuticals Inc. Company Information
  99. 7.17.2 Acadia Pharmaceuticals Inc. Business Overview
  100. 7.17.3 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  102. 7.17.5 Acadia Pharmaceuticals Inc. Recent Developments
8 North America
  1. 8.1 North America Targeted Drugs for Neurodegenerative Diseases Revenue (2021-2032)
  2. 8.2 North America Targeted Drugs for Neurodegenerative Diseases Revenue by Type (2021-2032)
  3. 8.2.1 North America Targeted Drugs for Neurodegenerative Diseases Revenue by Type (2021-2026)
  4. 8.2.2 North America Targeted Drugs for Neurodegenerative Diseases Revenue by Type (2027-2032)
  5. 8.3 North America Targeted Drugs for Neurodegenerative Diseases Revenue Share by Type (2021-2032)
  6. 8.4 North America Targeted Drugs for Neurodegenerative Diseases Revenue by Application (2021-2032)
  7. 8.4.1 North America Targeted Drugs for Neurodegenerative Diseases Revenue by Application (2021-2026)
  8. 8.4.2 North America Targeted Drugs for Neurodegenerative Diseases Revenue by Application (2027-2032)
  9. 8.5 North America Targeted Drugs for Neurodegenerative Diseases Revenue Share by Application (2021-2032)
  10. 8.6 North America Targeted Drugs for Neurodegenerative Diseases Revenue by Country
  11. 8.6.1 North America Targeted Drugs for Neurodegenerative Diseases Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Targeted Drugs for Neurodegenerative Diseases Revenue by Country (2021-2026)
  13. 8.6.3 North America Targeted Drugs for Neurodegenerative Diseases Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Targeted Drugs for Neurodegenerative Diseases Revenue (2021-2032)
  2. 9.2 Europe Targeted Drugs for Neurodegenerative Diseases Revenue by Type (2021-2032)
  3. 9.2.1 Europe Targeted Drugs for Neurodegenerative Diseases Revenue by Type (2021-2026)
  4. 9.2.2 Europe Targeted Drugs for Neurodegenerative Diseases Revenue by Type (2027-2032)
  5. 9.3 Europe Targeted Drugs for Neurodegenerative Diseases Revenue Share by Type (2021-2032)
  6. 9.4 Europe Targeted Drugs for Neurodegenerative Diseases Revenue by Application (2021-2032)
  7. 9.4.1 Europe Targeted Drugs for Neurodegenerative Diseases Revenue by Application (2021-2026)
  8. 9.4.2 Europe Targeted Drugs for Neurodegenerative Diseases Revenue by Application (2027-2032)
  9. 9.5 Europe Targeted Drugs for Neurodegenerative Diseases Revenue Share by Application (2021-2032)
  10. 9.6 Europe Targeted Drugs for Neurodegenerative Diseases Revenue by Country
  11. 9.6.1 Europe Targeted Drugs for Neurodegenerative Diseases Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Targeted Drugs for Neurodegenerative Diseases Revenue by Country (2021-2026)
  13. 9.6.3 Europe Targeted Drugs for Neurodegenerative Diseases Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Targeted Drugs for Neurodegenerative Diseases Revenue (2021-2032)
  2. 10.2 China Targeted Drugs for Neurodegenerative Diseases Revenue by Type (2021-2032)
  3. 10.2.1 China Targeted Drugs for Neurodegenerative Diseases Revenue by Type (2021-2026)
  4. 10.2.2 China Targeted Drugs for Neurodegenerative Diseases Revenue by Type (2027-2032)
  5. 10.3 China Targeted Drugs for Neurodegenerative Diseases Revenue Share by Type (2021-2032)
  6. 10.4 China Targeted Drugs for Neurodegenerative Diseases Revenue by Application (2021-2032)
  7. 10.4.1 China Targeted Drugs for Neurodegenerative Diseases Revenue by Application (2021-2026)
  8. 10.4.2 China Targeted Drugs for Neurodegenerative Diseases Revenue by Application (2027-2032)
  9. 10.5 China Targeted Drugs for Neurodegenerative Diseases Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Targeted Drugs for Neurodegenerative Diseases Revenue (2021-2032)
  2. 11.2 Asia Targeted Drugs for Neurodegenerative Diseases Revenue by Type (2021-2032)
  3. 11.2.1 Asia Targeted Drugs for Neurodegenerative Diseases Revenue by Type (2021-2026)
  4. 11.2.2 Asia Targeted Drugs for Neurodegenerative Diseases Revenue by Type (2027-2032)
  5. 11.3 Asia Targeted Drugs for Neurodegenerative Diseases Revenue Share by Type (2021-2032)
  6. 11.4 Asia Targeted Drugs for Neurodegenerative Diseases Revenue by Application (2021-2032)
  7. 11.4.1 Asia Targeted Drugs for Neurodegenerative Diseases Revenue by Application (2021-2026)
  8. 11.4.2 Asia Targeted Drugs for Neurodegenerative Diseases Revenue by Application (2027-2032)
  9. 11.5 Asia Targeted Drugs for Neurodegenerative Diseases Revenue Share by Application (2021-2032)
  10. 11.6 Asia Targeted Drugs for Neurodegenerative Diseases Revenue by Country
  11. 11.6.1 Asia Targeted Drugs for Neurodegenerative Diseases Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Targeted Drugs for Neurodegenerative Diseases Revenue by Country (2021-2026)
  13. 11.6.3 Asia Targeted Drugs for Neurodegenerative Diseases Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Targeted Drugs for Neurodegenerative Diseases Revenue (2021-2032)
  2. 12.2 SAMEA Targeted Drugs for Neurodegenerative Diseases Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Targeted Drugs for Neurodegenerative Diseases Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Targeted Drugs for Neurodegenerative Diseases Revenue by Type (2027-2032)
  5. 12.3 SAMEA Targeted Drugs for Neurodegenerative Diseases Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Targeted Drugs for Neurodegenerative Diseases Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Targeted Drugs for Neurodegenerative Diseases Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Targeted Drugs for Neurodegenerative Diseases Revenue by Application (2027-2032)
  9. 12.5 SAMEA Targeted Drugs for Neurodegenerative Diseases Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Targeted Drugs for Neurodegenerative Diseases Revenue by Country
  11. 12.6.1 SAMEA Targeted Drugs for Neurodegenerative Diseases Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Targeted Drugs for Neurodegenerative Diseases Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Targeted Drugs for Neurodegenerative Diseases Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst